{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T01:13:08Z","timestamp":1778029988513,"version":"3.51.4"},"reference-count":22,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"F2G Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoF"],"abstract":"<jats:p>There are scarce data comparing inpatient mortality, length of stay (LOS) and all-cause hospital costs in disseminated coccidioidomycosis (DCM) vs. isolated pulmonary coccidioidomycosis (IPCM). We assessed the burden of hospital illness associated with DCM versus IPCM. This study was performed using National Inpatient Sample data from 2019 to 2021. DCM was defined as having a primary International Classification of Diseases\u2014Tenth Revision (ICD-10) code for coccidioidal meningitis, a non-primary code for coccidioidal meningitis in the presence of a primary code for a meningitis complication or a procedure code depicting the need for a meningitis-related procedure, or a primary code for DCM without a code for unspecified disease. IPCM was defined as a primary code for pulmonary coccidioidomycosis without codes for DCM or unspecified disease. Multivariable regression was used to compare the odds of in-hospital mortality, LOS and all-cause hospital costs (2023 US$) for DCM versus IPCM, after covariate adjustment. A total of 6195 hospitalizations were identified, 2305 for DCM and 3890 for IPCM. Patients experiencing a DCM hospitalization had a 19.7% incidence of concomitant pulmonary coccidioidomycosis. Coccidioidal meningitis constituted 81.3% of all DCM hospitalizations, of which 78.1% received a meningitis-related procedure or were admitted for a meningitis complication. DCM was associated with an increased odds of death (odds ratio = 2.76, 95% confidence interval [CI] = 1.26\u20136.04) versus IPCM. DCM was associated with a longer mean hospital LOS (4.51 days, 95%CI = 3.39\u20135.63) and higher mean all-cause costs ($20,008, 95%CI = $15,313\u2013$24,704) versus IPCM. DCM hospitalizations were associated with higher odds of inpatient mortality, longer LOS, and higher costs versus IPCM.<\/jats:p>","DOI":"10.3390\/jof11020161","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T03:29:53Z","timestamp":1739935793000},"page":"161","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Burden of Hospital Illness Associated with Disseminated Versus Isolated Pulmonary Coccidioidomycosis in the United States"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4868-7158","authenticated-orcid":false,"given":"Craig I.","family":"Coleman","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, CT 06269, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Bylyku","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, CT 06269, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andria","family":"Latifi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, CT 06269, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belinda","family":"Lovelace","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research, F2G, Inc., Princeton, NJ 08540, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4715-0510","authenticated-orcid":false,"given":"Ryan","family":"Shan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, CT 06269, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lahar","family":"Miriyapalli","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, CT 06269, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6203-5693","authenticated-orcid":false,"given":"Fariba","family":"Donovan","sequence":"additional","affiliation":[{"name":"The Valley Fever Center for Excellence, University of Arizona College of Medicine-Tucson, Tucson, AZ 85724, USA"},{"name":"The Division of Infectious Diseases, Department of Medicine, University of Arizona College of Medicine-Tucson, Tucson, AZ 85724, USA"},{"name":"BIO5 Institute, University of Arizona, Tucson, AZ 85721, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s40121-022-00606-y","article-title":"Coccidioidomycosis: A Contemporary Review","volume":"11","author":"Crum","year":"2022","journal-title":"Infect. Dis. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/cid\/ciw538","article-title":"Executive Summary: 2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis","volume":"63","author":"Galgiani","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/cid\/ciac478","article-title":"Controversies in the Management of Central Nervous System Coccidioidomycosis","volume":"75","author":"Thompson","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.3201\/eid1611.100475","article-title":"Enhanced surveillance of coccidioidomycosis, Arizona, USA, 2007\u20132008","volume":"16","author":"Tsang","year":"2010","journal-title":"Emerg. Infect. Dis."},{"key":"ref_5","unstructured":"HCUP National Inpatient Sample (NIS) (2024, April 12). Healthcare Cost and Utilization Project (HCUP). 2019\u20132021. Agency for Healthcare Research and Quality, Rockville, MD, Available online: www.hcup-us.ahrq.gov\/nisoverview.jsp."},{"key":"ref_6","unstructured":"(2024, April 12). Healthcare Cost and Utilization Project, Agency for Healthcare Research and Quality. Producing National HCUP Estimates, Available online: https:\/\/hcup-us.ahrq.gov\/tech_assist\/nationalestimates\/508_course\/508course_2023.jsp."},{"key":"ref_7","unstructured":"(2024, April 12). Consumer Price Index, Available online: https:\/\/www.bls.gov\/cpi\/."},{"key":"ref_8","first-page":"368","article-title":"Hospitalized burden and outcomes of coccidioidomycosis: A nationwide analysis, 2005\u20132012","volume":"55","author":"Luo","year":"2017","journal-title":"Med. Mycol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1086\/500405","article-title":"Hospitalizations for endemic mycoses: A population-based national study","volume":"42","author":"Chu","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"ofab593","DOI":"10.1093\/ofid\/ofab593","article-title":"Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018","volume":"9","author":"Rayens","year":"2022","journal-title":"Open Forum. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1093\/cid\/ciy776","article-title":"Estimation of Direct Healthcare Costs of Fungal Diseases in the United States","volume":"68","author":"Benedict","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"ofac097","DOI":"10.1093\/ofid\/ofac097","article-title":"Economic Burden of Fungal Diseases in the United States","volume":"9","author":"Benedict","year":"2022","journal-title":"Open Forum. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"ofae706","DOI":"10.1093\/ofid\/ofae706","article-title":"Burden of Hospitalization for Coccidioidal Meningitis: An Analysis of the National Inpatient Sample, 2019\u20132021","volume":"11","author":"Coleman","year":"2024","journal-title":"Open Forum. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Wilson, L., Ting, J., Lin, H., Shah, R., MacLean, M., Peterson, M.W., Stockamp, N., Libke, R., and Brown, P. (2019). The Rise of Valley Fever: Prevalence and Cost Burden of Coccidioidomycosis Infection in California. Int. J. Environ. Res. Public Health, 16.","DOI":"10.3390\/ijerph16071113"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"ofaa623","DOI":"10.1093\/ofid\/ofaa623","article-title":"Clinical and Economic Burden of Valley Fever in Arizona: An Incidence-Based Cost-of-Illness Analysis","volume":"8","author":"Grizzle","year":"2020","journal-title":"Open Forum. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Benedict, K., Hennessee, I., Smith, D.J., Toda, M., and Thompson, G.R. (2025). Impact of fluconazole on outcomes of patients with primary pulmonary coccidioidomycosis: A commercial health insurance claims-based, propensity score matched analysis. Clin. Infect. Dis., ciaf036.","DOI":"10.1093\/cid\/ciaf036"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"ofad243","DOI":"10.1093\/ofid\/ofad243","article-title":"Challenges in the Long-term Management of Patients With Coccidioidal Meningitis: A Retrospective Analysis of Treatment and Outcomes","volume":"10","author":"Sivasubramanian","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.3201\/eid2509.190023","article-title":"Delays in Coccidioidomycosis Diagnosis and Associated Healthcare Utilization, Tucson, Arizona, USA","volume":"25","author":"Donovan","year":"2019","journal-title":"Emerg. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.3201\/eid2408.171595","article-title":"Enhanced Surveillance for Coccidioidomycosis, 14 US States, 2016","volume":"24","author":"Benedict","year":"2018","journal-title":"Emerg. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"882","DOI":"10.3201\/eid3005.231624","article-title":"Coccidioidomycosis-Related Hospital Visits, Texas, USA, 2016\u20132021","volume":"30","author":"Mayfield","year":"2024","journal-title":"Emerg. Infect. Dis."},{"key":"ref_21","first-page":"215","article-title":"Administrative databases and outcomes assessment: An overview of issues and potential utility","volume":"5","author":"Gandhi","year":"1999","journal-title":"J. Manag. Care Pharm."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.3201\/eid2705.204661","article-title":"Coccidioidomycosis and COVID-19 Co-Infection, United States, 2020","volume":"27","author":"Heaney","year":"2021","journal-title":"Emerg. Infect. Dis."}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/11\/2\/161\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:37:29Z","timestamp":1760027849000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/11\/2\/161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":22,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["jof11020161"],"URL":"https:\/\/doi.org\/10.3390\/jof11020161","relation":{},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]}}}